Farxiga Cost in South Dakota 2026: Cash Price, Insurance, and Compounded Dapagliflozin Options

What Does Farxiga Actually Cost in South Dakota in 2026?

The cash-pay retail price of Farxiga in South Dakota is approximately $620 per month in 2026, matching AstraZeneca's published list price. That figure assumes no insurance, no manufacturer card, and no discount program. Prices can vary by as much as 10 to 15 percent across individual pharmacies in Sioux Falls, Rapid City, and rural SD, so calling ahead is worth the two minutes it takes.

Dapagliflozin's cost sits in the same tier as most branded SGLT2 inhibitors. Empagliflozin (Jardiance) and canagliflozin (Invokana) carry comparable list prices, a reflection of the class rather than any single manufacturer's pricing decision. No FDA-approved generic dapagliflozin tablet existed as of mid-2025, so the brand price is effectively the floor for the branded product [1].

The FDA approved dapagliflozin under the Farxiga label for type 2 diabetes in 2014, for heart failure with reduced ejection fraction in 2020, and for chronic kidney disease in 2021 [2]. Each approval rested on large outcomes data. DAPA-HF (N=4,744) demonstrated that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (hazard ratio 0.74 to 95% CI 0.65 to 0.85, P<0.001) [3]. DAPA-CKD (N=4,304) showed a 39% relative reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal or CV death (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) [4].

Those outcomes matter to payers. They also explain why physicians are reluctant to discontinue the drug when a patient cannot afford it, which makes understanding every cost-reduction path a clinical priority, not just a financial one.

Does South Dakota Medicaid Cover Farxiga?

South Dakota Medicaid does not cover Farxiga for any of its FDA-approved indications as of 2026. This applies to the type 2 diabetes indication, the heart failure indication, and the chronic kidney disease indication. Medicaid formulary decisions in South Dakota are managed through the SD Department of Social Services, and dapagliflozin has not appeared on the preferred drug list for fee-for-service Medicaid beneficiaries [5].

That gap is clinically significant. The American Diabetes Association's 2024 Standards of Care explicitly recommend SGLT2 inhibitors for patients with type 2 diabetes and established heart failure or CKD, regardless of baseline HbA1c [6]. South Dakota Medicaid beneficiaries who meet those criteria face a direct mismatch between guideline-recommended therapy and available coverage.

Dual-eligible patients (Medicare-Medicaid) may have a different path. Medicare Part D plans vary by formulary. In 2026, some Part D plans in the SD market place Farxiga on Tier 3 or Tier 4, producing out-of-pocket costs between $47 and $200 per month after the Medicare Prescription Payment Plan smoothing option. Patients should run a formulary check at medicare.gov or ask their plan's pharmacy help line directly.

Medicaid Managed Care Organizations operating in South Dakota may apply their own formularies. Patients enrolled in a managed care plan rather than fee-for-service SD Medicaid should request a formulary exception in writing, supported by a letter of medical necessity from their prescriber citing DAPA-HF [3] or DAPA-CKD [4] outcomes data.

Is Compounded Dapagliflozin Legal in South Dakota?

Compounded dapagliflozin is legally available to South Dakota residents through state-licensed 503A compounding pharmacies operating under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies: they may prepare drug compounds for individual patients when a licensed prescriber writes a prescription and the compound is not commercially available in a form that meets the patient's clinical need [7].

South Dakota follows federal law on this point and does not impose additional state prohibitions on dapagliflozin compounding. The SD Board of Pharmacy licenses and inspects 503A facilities within the state and accepts valid prescriptions from out-of-state licensed pharmacies shipping to SD patients, provided those pharmacies hold appropriate licensure [8].

Compounded dapagliflozin is not FDA-approved. It has not passed the same bioequivalence testing required of brand or generic drug products. Absorption, purity, and potency can vary between compounding labs. Patients and prescribers accepting this route should request a certificate of analysis from the pharmacy for each batch. HealthRX clinicians review these certificates as part of the prescribing workflow when compounded dapagliflozin is considered for a patient.

Cost is the main driver of interest. Several 503A pharmacies serving SD patients price compounded oral dapagliflozin between $40 and $80 per month, a reduction of 85 to 94 percent compared to the brand list price. Some telehealth platforms, including HealthRX, bundle the pharmacy cost into a monthly membership fee, effectively bringing the out-of-pocket drug cost to near zero for enrolled patients.

The HealthRX prescribing team applies a three-tier decision framework when evaluating dapagliflozin access for South Dakota patients: (1) confirm insurance coverage and copay tier; (2) if uninsured or coverage is denied, apply the AstraZeneca savings card and document the result; (3) if the savings card is inaccessible or the patient remains uninsured without commercial coverage, evaluate compounded dapagliflozin through a licensed 503A pharmacy with batch COA review. This framework reduces the median time to first fill for SD HealthRX patients from 11 days to 4 days based on internal intake data.

Which Insurance Plans Cover Farxiga in South Dakota?

Commercial insurance coverage for Farxiga in South Dakota depends on the specific plan, the indication documented on the prescription, and whether a prior authorization is required. Most major commercial payers operating in SD, including Sanford Health Plan, Wellmark BCBS, and Avera Health Plans, place Farxiga on Tier 3 or Tier 4 specialty formulary tiers when covered [9].

Tier 3 placement typically means a copay between $40 and $100 per 30-day supply after deductible. Tier 4 (non-preferred brand) can push that to $150 to $300. Prior authorization is common for the CKD and heart failure indications. The PA criteria generally require documented eGFR values, HbA1c, or echocardiographic ejection fraction consistent with the approved label, so having labs in hand before submission shortens approval time.

Employer self-funded plans in South Dakota may follow different formulary rules than their insurer's standard commercial book. HR departments can request a formulary exception on behalf of employees. Patients who are denied coverage should request a peer-to-peer review between their prescriber and the plan's medical director, citing DAPA-HF outcomes [3] and the 2024 ADA Standards of Care recommendation [6].

The AHA/ACC 2022 Guideline for the Diagnosis and Management of Heart Failure provides a Class I, Level of Evidence A recommendation for SGLT2 inhibitors in patients with HFrEF, stating: "SGLT2 inhibitors are recommended to decrease HF hospitalizations and CV mortality in patients with symptomatic chronic HFrEF." [10] Presenting that language during an insurance appeal carries real weight with plan medical directors.

How the AstraZeneca Savings Card Works in South Dakota

The AstraZeneca Farxiga savings card (also called the AZ&Me or AstraZeneca Access 360 commercial copay program) is available to South Dakota patients who carry commercial insurance. Eligible patients pay as little as $0 per month, with AstraZeneca covering the remainder up to a defined annual cap [11].

Eligibility requires: (1) a valid Farxiga prescription from a licensed US prescriber; (2) commercial insurance (not Medicare, not Medicaid, not any federal or state government program); (3) residency in the United States. South Dakota residents who meet all three criteria qualify the same as residents of any other state.

The card is activated online at AstraZeneca's patient support portal or by calling AZ&Me at 1-800-292-6363. Pharmacists at Walgreens, Rite Aid, and most independent SD pharmacies can process the card at point of sale. The savings card does not apply to Medicaid beneficiaries. For those patients, the AZ&Me Patient Assistance Program offers free medication to uninsured or underinsured patients whose household income falls below 400 percent of the federal poverty level [11].

Patients on Medicare who hit the standard deductible phase or coverage gap should check whether their Part D plan has a supplemental manufacturer agreement. As of 2026, the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D applies, which meaningfully limits exposure for Medicare beneficiaries regardless of tier placement [12].

Can I Get a Farxiga Prescription via Telehealth in South Dakota?

Telehealth prescribing of Farxiga is permitted in South Dakota. Licensed physicians and nurse practitioners in South Dakota (or those holding SD telehealth licensure) may prescribe Farxiga following a synchronous audio-video evaluation that establishes an appropriate patient-provider relationship under SD codified law [13].

Dapagliflozin is not a controlled substance. It does not carry the additional prescribing restrictions that apply to Schedule II through V drugs. The Ryan Haight Act limitations on telemedicine prescribing do not apply. A telehealth visit that documents indication, relevant labs (creatinine, eGFR, HbA1c, urine albumin-to-creatinine ratio as appropriate), contraindications, and patient education satisfies the standard of care for initiating this drug remotely [14].

South Dakota's geography makes telehealth particularly relevant. Roughly 75 percent of the state's counties qualify as rural or frontier under HRSA classification, and endocrinology and nephrology specialists are concentrated in Sioux Falls and Rapid City [15]. Patients managing type 2 diabetes, CKD, or heart failure in western SD counties often travel more than 100 miles for specialty care. A telehealth visit eliminates that barrier while maintaining access to guideline-based therapy.

HealthRX clinicians conduct SD telehealth visits for dapagliflozin initiation and ongoing management. The intake process reviews recent HbA1c, eGFR, blood pressure, and current medication list to confirm the drug is appropriate and identify any contraindications, including active urinary tract infection, eGFR below 25 mL/min/1.73m² for the diabetes indication, or a history of recurrent genital mycotic infections.

What Are the Real Alternatives If Farxiga Remains Unaffordable?

When Farxiga remains out of reach despite the savings card and compounding options, several SGLT2 inhibitor alternatives exist. Empagliflozin (Jardiance, Eli Lilly/Boehringer Ingelheim) and canagliflozin (Invokana, Janssen) carry similar list prices but have distinct formulary placements on SD commercial plans. A prescriber willing to submit a therapeutic substitution request may find that one of those agents lands on a lower copay tier for a specific patient's plan [16].

Metformin remains the lowest-cost oral diabetes medication, available at Walmart and most SD pharmacies for $4 to $9 per 30-day supply, though it does not carry the cardiovascular or renal outcomes data of SGLT2 inhibitors [6]. For heart failure patients specifically, there is no direct substitute for an SGLT2 inhibitor from a guideline standpoint. The 2022 AHA/ACC Heart Failure Guideline does not list an equivalent alternative agent with Class I evidence for reducing HF hospitalizations through a non-SGLT2 mechanism [10].

GLP-1 receptor agonists address overlapping cardiovascular risk in type 2 diabetes patients and may be covered on formularies where Farxiga is not. LEADER (N=9,340) showed liraglutide reduced major adverse cardiovascular events by 13% relative to placebo (HR 0.87 to 95% CI 0.78 to 0.97, P<0.001 for non-inferiority, P=0.01 for superiority) [17]. SUSTAIN-6 (N=3,297) showed semaglutide 0.5 mg and 1 mg reduced MACE by 26% (HR 0.74 to 95% CI 0.58 to 0.95, P<0.001 for non-inferiority) [18]. Neither agent replicates dapagliflozin's specific renal or HFrEF benefit, but a cardiometabolic medicine approach using the most accessible agent first is sometimes the pragmatic starting point.

Monitoring Requirements That Affect Ongoing Cost

Starting dapagliflozin is not the only cost to plan for. Ongoing monitoring adds to the total picture. FDA labeling for Farxiga requires periodic assessment of renal function (serum creatinine and eGFR) before initiation and at regular intervals, particularly in patients with CKD [2]. The DAPA-CKD protocol used eGFR measurements every four months during the 2.4-year median follow-up [4]. Most SD prescribers align with a similar interval.

Urinalysis for glycosuria, urine albumin-to-creatinine ratio, and HbA1c (for diabetic patients) are standard monitoring parameters. For heart failure patients, clinical assessment of volume status, blood pressure, and potassium every three to six months is consistent with AHA/ACC 2022 guidance [10]. These labs are generally covered by insurance even when the drug itself is not, but patients on high-deductible plans should budget for lab costs of $40 to $120 per panel depending on facility and payer.

Telehealth platforms including HealthRX can order labs through national reference labs, with results reviewed asynchronously before the follow-up visit. This workflow keeps total monitoring cost lower for SD patients who would otherwise need an in-person office visit for each lab review.

South Dakota-Specific Resources for Farxiga Access

Several state and national programs apply specifically to South Dakota patients who cannot afford Farxiga through standard channels.

The AZ&Me Patient Assistance Program, as noted, provides free Farxiga to uninsured or underinsured SD residents below 400 percent FPL. Applications are completed online or by phone and require income documentation and prescriber sign-off [11]. Processing takes approximately 10 to 14 business days for first-time applicants.

The NeedyMeds database (needymeds.org) catalogs copay assistance and patient assistance programs by drug name. South Dakota residents can search dapagliflozin and find both the AZ&Me program and any third-party charitable programs that may apply to their situation [19].

GoodRx and similar coupon aggregators list retail prices for Farxiga across SD zip codes. As of mid-2025, GoodRx coupons in Sioux Falls bring the cash price to approximately $520 to $560 per month, a modest reduction from list price. These coupons cannot be combined with insurance and do not satisfy Part D true-out-of-pocket tracking [20].

South Dakota's State Health Insurance Assistance Program (SHIP) provides free counseling to Medicare beneficiaries on plan selection, including formulary comparison for drugs like Farxiga. SD SHIP can be reached at 1-800-536-8197. SHIP counselors can run a side-by-side formulary comparison across all Part D plans available in a patient's county, which often identifies a plan with meaningfully lower Farxiga cost than the patient's current coverage [21].

For the majority of commercially insured South Dakota patients who activate the AstraZeneca savings card, the effective monthly cost of Farxiga is $0. Confirm eligibility at AstraZeneca's Access 360 portal before assuming the full $620 list price applies to your situation.